Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

26.03.2015: WILEX announces financial figures for the 2014 financial year and reports on course of business.WILEX AG today published its financial results and annual report for the 2014 financial year (1 December 2013 – 30 November 2014).  ....More


Seite gelesen: 244240 | Heute: 3